SCHEMBL868592

SCHEMBL868592

O=C1CCC(N2Cc3c(Cl)cccc3C2=O)C(=O)N1

nearest known ligand 0.75

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 14/20 0.75
IKZF3 Q9UKT9 8/20 0.73
TNF P01375 4/20 0.73
IL1B P01584 4/20 0.73
IKZF1 Q13422 3/20 0.73
DDB1 Q16531 3/20 0.73
BRD4 O60885 1/20 0.73
CSNK1A1 P48729 1/20 0.58
ALDH1A1 P00352 1/20 0.55
CHRM2 P08172 1/20 0.55
OPRM1 P35372 1/20 0.55
GSPT1 P15170 1/20 0.55
CYP1A2 P05177 1/20 0.55
TSHR P16473 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
IKZF2 Q9UKS7 2/20 0.54
MAP1LC3B Q9GZQ8 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18270889 0.93 CRBN (0.65) CRBNIKZF3TNFIL1BIKZF1
SCHEMBL25231161 0.86 CRBN (0.70) CRBNIKZF3TNFIL1BIKZF1
SCHEMBL20442491 0.86 CRBN (1.00) CRBNIKZF3TNFIL1BIKZF1
SCHEMBL29453150 0.86 CRBN (1.00) CRBNIKZF3TNFIL1BIKZF1
SCHEMBL1097880 0.86 CRBN (1.00) CRBNIKZF3TNFIL1BIKZF1
SCHEMBL25031818 0.86 CRBN (0.77) CRBNIKZF3TNFIL1BIKZF1
SCHEMBL19973047 0.86 CRBN (0.77) CRBNIKZF3TNFIL1BIKZF1
SCHEMBL31727916 0.86 CRBN (1.00) CRBNIKZF3TNFIL1BIKZF1
SCHEMBL25233562 0.85 CRBN (0.72) CRBNIKZF3TNFIL1BIKZF1
SCHEMBL3543582 0.85 CRBN (0.72) CRBNIKZF3TNFIL1BIKZF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230111853-A1 COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION ORIONIS BIOSCIENCES, INC. 2023-04-13 US disclosed
WO-2021126973-A1 COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION ORIONIS BIOSCIENCES, INC. (US) 2021-06-24 WO disclosed
US-9522899-B2 Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof NANJIAN CAVENDISH BIO-ENGINEERING TECHNOLOGY CO., LTD (CN) 2016-12-20 US disclosed
US-9522899-B2 Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof NANJIAN CAVENDISH BIO-ENGINEERING TECHNOLOGY CO., LTD (CN) 2016-12-20 US disclosed
US-20150284359-A1 Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2015-10-08 US disclosed
US-20150284359-A1 Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2015-10-08 US disclosed
US-20150284329-A1 Methods for synthesizing 3-(Substituted Dihydroisoindolinone-2-YI)-2, 6-Dioxopiperidine, and intermediates thereof Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2015-10-08 US disclosed
US-9085530-B2 Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2015-07-21 US disclosed
US-9085530-B2 Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2015-07-21 US disclosed
EP-2438053-B1 METHODS FOR SYNTHESIZING 3-(SUBSTITUTED DIHYDROISOINDOLINONE-2-YL)-2,6-DIOXOPIPERIDINE, AND INTERMEDIATES THEREOF NANJING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD (CN) 2013-09-11 EP disclosed
EP-2438053-B1 METHODS FOR SYNTHESIZING 3-(SUBSTITUTED DIHYDROISOINDOLINONE-2-YL)-2,6-DIOXOPIPERIDINE, AND INTERMEDIATES THEREOF NANJING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD (CN) 2013-09-11 EP disclosed
US-20120077982-A1 Methods for Synthesizing 3-(Substituted Dihydroisoindolinone-2-YL)-2, 6-Dioxopiperidine, and Intermediates Thereof Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2012-03-29 US disclosed
US-20120077982-A1 Methods for Synthesizing 3-(Substituted Dihydroisoindolinone-2-YL)-2, 6-Dioxopiperidine, and Intermediates Thereof Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2012-03-29 US disclosed
WO-2010139266-A1 METHODS FOR SYNTHESIZING 3-(SUBSTITUTED DIHYDROISOINDOLINONE-2-YL)-2,6-DIOXOPIPERIDINE, AND INTERMEDIATES THEREOF Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230111853-A1 COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION CRBN, STUB1, ADRM1 CRBN 1/4885IKZF3 463/4885TNF 3692/4885
US-20150284329-A1 Methods for synthesizing 3-(Substituted Dihydroisoindolinone-2-YI)-2, 6-Dioxopiperidine, and intermediates thereof DHPS, QDPR, FDPS CRBN 4352/4885IKZF3 1195/4885TNF 1790/4885
US-20120077982-A1 Methods for Synthesizing 3-(Substituted Dihydroisoindolinone-2-YL)-2, 6-Dioxopiperidine, and Intermediates Thereof DHPS, QDPR, FDPS CRBN 4078/4885IKZF3 1593/4885TNF 2065/4885
US-20150284359-A1 Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof DHPS, QDPR, FDPS CRBN 4078/4885IKZF3 1593/4885TNF 2065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.